Effects on kidney disease, fertility and development in mice inheriting a protein-truncating Denys-Drash syndrome allele (Wt1 tmT396)

Transgenic Research

Volumn 17, Issue 3, 2008, Pages 459-475

  Patek, Charles E ^a   Brownstein, David G ^b   Fleming, Stewart ^c   Wroe, Caroline ^d   Rose, Lorraine ^a   Webb, Anna ^e,f   Berry, Rachel L ^a,e   Devenney, Paul S ^a,e   Walker, Marion ^a   Maddocks, Oliver D K ^a   Lawrence, Nicola J ^a,g   Harrison, David J ^a   Wood, Katrina M ^h   Miles, Colin G ^d   Hooper, Martin L ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d INSTITUTE OF HUMAN GENETICS   (United Kingdom)

^e WESTERN GENERAL HOSPITAL   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Adrenal gland; Denys Drash syndrome; Gonad; Kidney; Liver; WT1

Indexed keywords

WT1 PROTEIN;

ALLELE; ANIMAL; ARTICLE; C57BL MOUSE; CBA MOUSE; CROSS BREEDING; DENYS DRASH SYNDROME; DOMINANT GENE; EMBRYO (ANATOMY); FEMALE; FERTILITY; GENE DOSAGE; GENE TARGETING; GENETICS; GROWTH, DEVELOPMENT AND AGING; HETEROZYGOSITY LOSS; KIDNEY DISEASE; MALE; METHODOLOGY; MOLECULAR CLONING; MOUSE; PHYSIOLOGY; TRANSGENIC MOUSE;

ALLELES; ANIMALS; CLONING, MOLECULAR; CROSSES, GENETIC; DENYS-DRASH SYNDROME; EMBRYO, MAMMALIAN; FEMALE; FERTILITY; GENE DOSAGE; GENE TARGETING; GENES, DOMINANT; GROWTH AND DEVELOPMENT; KIDNEY DISEASES; LOSS OF HETEROZYGOSITY; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; WT1 PROTEINS;

MUS;

EID: 42549155256     PISSN: 09628819     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11248-007-9157-0     Document Type: Article

References (59)

1. Auber F, Lortat-Jacob S, Sarnacki S, Jaubert F, Salmon R, Thibaud E, Jeanpierre C, Nihoul-Fekete C (2003) Surgical management and genotype/phenotype correlations in WT1 gene-related diseases (Drash, Frasier syndromes). J Pediatr Surg 38:124-129
2. Aubin-Houzelstein G, Da Silva NR, Bellier S, Salaun P, Montagutelli X, Panthier JJ (2003) Genetic interaction between a maternal factor and the zygotic genome controls the intestine length in PRM/Alf mice. Physiol Genom 16:82-89
3. Borel F, Barilla KC, Hamilton TB, Iskandar M, Romaniuk PJ (1996) Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1. Biochemistry 35:12070-12076
4. Breslow NE, Takashima JR, Ritchey ML, Strong LC, Green DM (2000) Renal failure in the Denys-Drash and Wilms' tumour-aniridia syndromes. Cancer Res 60:4030-4032
5. Bruening W, Moffett P, Chia S, Heinrich G, Pelletier J (1996) Identification of nuclear localisation signals within the zinc fingers of the WT1 tumor suppressor gene product. FEBS Lett 393:41-47
6. Coppes MJ, Liefers GJ, Higuchi M, Zinn AB, Balfe JW, Williams BRG (1992) Inherited WT1 mutation in Denys-Drash Syndrome. Cancer Res 52:6125-6128
7. Dallosso AR, Hancock AL, Brown KW, Williams AC, Jackson S, Malik K (2004) Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms' tumours. Hum Mol Genet 13:405-415
8. Davies RC, Calvio C, Bratt E, Larsson SH, Lamond AL, Hastie N (1998) WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes. Genes Dev 12:3217-3225
9. Discenza MT, Pelletier J (2004) Insights into the physiological role of WT1 from studies of genetically modified mice. Physiol Genom 16:287-300
10. Donovan MJ, Natoli TA, Sainio K, Amstutz A, Jaenisch R, Sariola H, Kreidberg JA (1999) Initial differentiation of the metanephric mesenchyme is independent of WT1 and the ureteric bud. Dev Genet 24:252-262
11. Drummond IA, Rupprecht HD, Rohwer-Nutter P, Lopez-Guisa JM, Madden SL, Rauscher FJ, Sukhatme VP (1994) DNA recognition by splicing variants of the Wilms' tumor suppressor, WT1. Mol Cell Biol 14:3800-3809
12. Dutton JR, Lahiri D, Ward A (2006) Different isoforms of the Wilms' tumour protein WT1 have distinct patterns of distribution and trafficking within the nucleus. Cell Prolif 39:519-535
13. Englert C, Vidal M, Maheswaran S, Ge Y, Ezzell RM, Isslbacher KJ, Haber DA (1995) Truncated WT1 mutants alter the subnuclear localisation of the wild-type protein. Proc Natl Acad Sci USA 92:11960-11964
14. +/R394W mouse displays glomerulosclerosis and early onset renal failure characteristic of human Denys-Drash syndrome. Mol Cell Biol 24:9899-9910
15. Glaser T, Lane J, Housman D (1990) A mouse model of the aniridia-Wilms' tumour deletion syndrome. Science 250:823-827
16. Guo JK, Menke AL, Gubler MC, Clarke AR, Harrison D, Hammes A, Hastie ND, Schedl A (2002) WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis. Hum Mol Genet 15:651-659
17. Hammes A, Guo J, Lutsch G, Leheste JR, Landrock D, Ziegler U, Gubler MC, Schedl A (2001) Two splice variants of the Wilms' tumour 1 gene have distinct functions during sex determination and nephron formation. Cell 106:319-329
18. Heathcott RW, Morison IM, Gubler MC, Corbett R, Reeve AE (2002) A review of the phenotypic variation due to the Denys-Drash syndrome-associated germline WT1 mutation R362X. Hum Mutat 19:462-466
19. Herrera E, Amusquivar E, Lopez-Soldado I, Ortega H (2006) Maternal lipid metabolism and placental lipid transfer. Hormone Res 65(Suppl 3):59-64
20. Herzer U, Crocoll A, Barton D, Howells N, Englert C (1999) The Wilms' tumor suppressor gene wt1 is required for development of the spleen. Curr Biol 9:837-840
21. Hohenstein P, Hastie ND (2006) The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet 15:R196-R201
22. Holmes G, Boterashvili S, English M, Wainwright B, Licht J, Little M (1997) Two N-terminal self-association domains are required for the dominant negative transcriptional activity of WT1 Denys-Drash mutant proteins. Biochem Biophys Res Comm 233:723-728
23. Hossain A, Saunders GF (2001) The human sex-determining gene SRY is a direct target of WT1. J Biol Chem 276:16817-16823
24. Hossain A, Nixon M, Kuo MT, Saunders GF (2006) N-terminally truncated WT1 protein with oncogenic properties overexpressed in leukaemia. J Biol Chem 281:28122-28130
25. IJpenberg A, Perez-Pomares JM, Guadix JA, Carmona R, Portillo-Sanchez V, Macias D, Hohenstein P, Miles CG, Hastie ND, Munoz-Chapuli R (2007) Wt1 and retinoic acid signalling are essential for stellate cell development and liver morphogenesis. Dev Biol, in press (Published online 18 Sept 2007, doi: 10.1016/j.ydbio.2007.09.014 )
26. Kaltenis P, Schumacher V, Jankauskiene A, Laurinavicius A, Royer-Pokora B (2004) Slow progressive FSGS associated with a F392L WT1 mutation. Paediatr Nephrol 19:353-356
27. Kanato K, Hosen N, Yanagihara M, Nakagata N, Shirakata T, Nakazawa T, Nishida S, Tsuboi A, Kawakami M, Masuda T, Oka Y, Oji Y, IJpenberg A, Hastie ND, Sugiyama H (2005) The Wilms' tumour gene WT1 is a common marker of progenitor cells in fetal liver. Biochem Biophys Res Comm 326:836-843
28. Kreidberg JA, Sariola H, Loring JM Maeda M, Pelletier J, Housman D, Jaenisch R (1993) WT1 is required for early kidney development. Cell 74:677-691
29. Kreidberg JA, Natoli TA, McGinnis L, Donovan M, Biggers JD, Amstutz A (1999) Coordinate action of Wt1 and a modifier gene supports embryonic survival in the oviduct. Mol Reprod Develop 52:366-375
30. Lahiri D, Dutton JR, Duarte A, Moorwood K, Graham CF, Ward A (2007) Nephropathy and defective spermatogenesis in mice transgenic for a single isoform of the Wilms' tumour suppressor protein, WT1-KTS, together with one disrupted Wt1 allele. Mol Reprod Dev 74:300-311
31. Larsson SH, Charlieu JP, Miyagawa K, Engelkamp D, Rassoulzadegan M, Ross A, Cuzin F, van Heyningen V, Hastie ND (1995) Subnuclear localisation of WT1 in splicing or transcription factor domains is regulated by alternative splicing. Cell 81:391-401
32. Little S, Hanks S, King-Underwood L, Picton S, Cullinane C, Rapley E, Rahman N, Pritchard-Jones K (2005) A WT1 exon 1 mutation in a child diagnosed with Denys-Drash syndrome. Pediatr Nephrol 20:81-85
33. Magin TM, McWhir J, Melton DW (1992) A new mouse embryonic stem cell line with good germline transmission and gene targeting frequency. Nucl Acid Res 20:3795-3706
34. McCullagh P, Nelder JA (1989) Generalised linear models, 2nd edn. Chapman and Hall, London
35. McTaggart SJ, Algar E, Chow CW, Powell HR, Jones CL (2001) Clinical spectrum of Denys-Drash and Frasier syndromes. Pediat Nephrol 16:335-339
36. Menke AL, IJpenberg A, Fleming S, Ross A, Medine CN, Patek CE, Spraggon L, Hughes J, Clarke AR, Hastie ND (2003) The WT1-heterozygous mouse: a model to study the development of glomerular sclerosis. J Path 200:667-674
37. Moffett P, Bruening W, Nakagama H, Bardeesy N, Housman D, Housman DE, Pelletier J (1995) Antagonism of WT1 activity by protein self-association. Proc Natl Acad Sci USA 92:11105-11109
38. Moore AW, Schedl A, McInnes L, Doyle M, Hecksher-Sorensen J, Hastie ND (1998) YAC transgenic analysis reveals Wilms' Tumour 1 gene activity in the proliferating coelomic epithelium, developing diaphragm and limb bud. Mech Dev 79:169-184
39. Moore AW, McInnes L, Kreidberg J, Hastie ND, Schedl A (1999) YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal gland and throughout nephrogenesis. Development 126:1845-1857
40. Nachtigal MW, Hirokawa Y, Enyeart-VanHouten DL, Flanagan JH Hammer GD, Ingraham HA (1998) Wilms' tumor 1 and Dax-1 modulate the Orphan Nuclear Receptor SF-1 in sex-specific gene expression. Cell 93:445-454
41. Niaudet P, Gubler MC (2006) WT1 and glomerular diseases. Pediatr Nephrol 21:1653-1660
42. Nordenskjold KA, Friedman E, Anvret M (1994) WT1 mutations in patients with Denys-Drash syndrome: a novel mutation in exon 8 and paternal allele origin. Hum Genet 93:115-120
43. Patek CE, Little MH, Fleming S, Miles C, Charlieu JP, Clarke AR, Miyagawa K, Christie S, Doig J, Harrison DJ, Porteous DJ, Brookes AJ, Hooper ML, Hastie ND (1999) A zinc finger truncation of murine WT1 results in the characteristic urogenital abnormalities of Denys-Drash syndrome. Proc Natl Acad Sci USA 96:2931-2936
44. Patek CE, Fleming SF, Miles CG, Bellamy CO, Ladomery M, Spraggon L, Mullins J, Hastie ND, Hooper ML (2003) Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis. Hum Mol Genet 12:2379-2394
45. Rae FK, Martinez G, Gillinder KR, Smith A, Shooter G, Forrest AR, Grimmond SM, Little MH (2004) Analysis of complementary expression profiles following WT1 induction versus expression reveals the cholesterol/fatty acid synthetic pathways as a possible major target of WT1. Oncogene 23:3067-3079
46. Reddy JC, Morris JC, Wang J, English MA, Haber DA, Shi Y, Licht JD (1995) WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins. J Biol Chem 270:10878-10884
47. Sainio K, Hellstedt P, Keridberg JA, Saxen L, Sariola H (1997) Differential regulation of two sets of mesonephric tubules by WT-1. Development 124:1293-1299
48. Sass B (1996) Embryology, adrenal gland, mouse. In: Capen CC, Jones TC, Mohr U (eds) Endocrine system. Springer-Verlag, Berlin, pp 381-386
49. Schumacher VA, Scharer K, Wuhl E, Altrogge H, Bonzel KE, Guschmann M, Neuhaus TJ, Pollastro RM, Kuwertz-Broking E, Bulla M, Tondera A-M, Mundel P, Helmchen U, Waldherr R, Weirich A, Royer-Pokora B (1998) Spectrum of early onset nephrotic syndrome associated with WT1 missense mutations. Kidney Int 53:1594-1600
50. Sokal RR, Rohlf FJ (1995) Biometry, 3rd edn. W. H. Freeman, New York
51. Tajinda K, Carroll J, Roberts CT (1999) Regulation of insulin-like growth factor 1 receptor promoter activity by wild-type and mutant versions of the WT1 tumor suppressor. Endocrinology 140:4713-4724
52. Vajjhala PR, Macmillan E, Gonad T, Little M (2003) The Wilms' tumour suppressor protein, WT1, undergoes CRM1-independent nucleocytoplasmic shuttling. FEBS Lett 554:143-148
53. Vicanek C, Ferretti E, Goodyer C, Torban E, Moffet P, Pelletier J, Goodyer P (1997) Regulation of renal EGF receptor expression in normal kidney and in Denys-Drash syndrome. Kidney Int 52:614-619
54. Wagner K-D, Wagner N, Vidal VPI, Schley G, Wilhelm D, Schedl A, Englert C, Scholz H (2002) The Wilms' tumor gene Wt1 is required for normal development of the retina. EMBO J 21:1389-1405
55. Wagner KJ, Patek CE, Miles C, Christie S, Brookes AJ, Hooper ML (2001) Truncation of WT1 results in downregulation of cyclin G1 and IGFBP-4 expression. Bioch Biophys Res Comm 287:977-982
56. Wagner N, Wagner K-D, Hammes A, Kirschne KM, Vidal VP, Schedl A, Scholz H (2005) A splice variant of the Wilms' tumor gene Wt1 is required for normal development of the olfactory system. Development 132:1327-1336
57. Watanabe N, Nakadate H, Haruta M, Sugawara W, Sasaki F, Tsunematsu Y, Kikuta A, Fukuzawa M, Okita H, Hata J, Soejima H, Kaneko Y (2006) Association of 11q loss, trisomy 12, and possible 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor. Genes Chromosomes Cancer 45:592-601
58. Waterston RH, Lindblad-Toh K, Birney E, Rogers J, Abril JF, Agarwal P, Agarwala R, Ainscough R, Alexandersson M, An P et al. (2002) Initial sequencing and comparative analysis of the mouse genome. Nature 420:520-562
59. Yoshida S, Wada Y (2005) Transfer of maternal cholesterol to embryo and fetus in pregnant mice. J Lipid Res 46:2168-2174